
Accure Therapeutics secures $1.6M from Michael J. Fox Foundation and Luxembourg national research Fund
Barcelona neuroscience R&D company Accure Therapeutics has received two grants totalling €1.46 million for two separate development programs on its drug candidate ACT-02. ACT-02 is a novel asset with disease-modifying potential, inhibiting Prolyl …